Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cutaneous Toxicities of Cancer Therapy in Hispanic and Latino Adults.

Created on 14 Oct 2026

Authors

Alondra Soto-González, Kerely Lorenzo-Méndez, Itzamar Pastrana-Echevarría, Sariemma Méndez-Rodríguez, Andrea Ortiz-Echevarría, Laura S Bermúdez-Martínez, Fabiana D García-Muñoz, Laura I Ortiz-López, Zelma C Chiesa Fuxench

Published in

Cutis. Volume 118. Issue 2. Pages 56-59.

Abstract

Cutaneous toxicities are common during cancer therapy and can affect treatment adherence and quality of life but often are underrecognized. Hispanic and Latino patients, many with darker skin tones, may face unique challenges in the presentation, recognition, and long-term effects. In our literature review, reported toxicities included dermatitis, vitiligo, rash, maculopapular exanthema, panniculitis, nail toxicity, and other hypersensitivity reactions. Radiotherapy toxicities were most consistently reported, with rates of moderate to severe dermatitis similar to prior research, but patients with skin of color often experienced more persistent pigmentary changes and long-term symptoms. Immune checkpoint inhibitor toxicities were reported less consistently, and limited representation prevented meaningful assessment of differences by ethnicity. Overall, this review highlights the need for better reporting and more inclusive research on dermatologic toxicities in Hispanic and Latino patients undergoing cancer treatment.

PMID:
42868301
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement